BioPharma Resources

Investigational drug · Phase 3

VC004

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Locally Advanced Solid Tumor.

Phase 3

Last checked: Nov 19, 2026Latest source record: Jul 27, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

6

Any phase or sponsor naming "VC004"

First trial start

2025

Mar 17, 2025

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "VC004", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Locally Advanced Solid Tumor

Approved drugs for the same conditions: Oncology

Largest trials

Live from ClinicalTrials.gov: studies naming "VC004" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 4 on PubMed

Also in development for Locally Advanced Solid Tumor

  • NeladalkibNVL-655Phase 32 trials

    Nuvalent Inc. · Non-small Cell Lung Cancer, Anaplastic Lymphoma Kinase-positive, Locally Advanced Solid Tumor

  • TNG462Phase 23 trials

    Tango Therapeutics, Inc. · MTAP-deleted Solid Tumors, Locally Advanced Solid Tumor, PDAC

  • FMC-376Phase 22 trials

    Frontier Medicines Corporation · Advanced Solid Tumors With KRAS G12C Mutations, Solid Tumor, Adult, Unresectable Solid Tumor

  • FMC-242Phase 21 trial

    Frontier Medicines Corporation · Locally Advanced Solid Tumor

  • FOG-001Phase 21 trial

    Parabilis Medicines, Inc. · Cancer, Colorectal Cancer, Solid Tumor

  • IPN60300Phase 21 trial

    Ipsen · Locally Advanced Solid Tumor, Metastatic Solid Tumor

  • TST003Phase 21 trial

    Transcenta Therapeutics (Hangzhou) Co., Ltd. · Locally Advanced Solid Tumor, Metastatic Tumor, Colorectal Adenocarcinoma

  • YH32364Phase 21 trial

    Yuhan Corporation · EGFR Overexpression, Locally Advanced Solid Tumor, Metastatic Solid Tumor

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.